4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alebund Pharmaceuticals (Jiangsu) Limited (9637) operates in the Drug Manufacturers - General industry and is headquartered in Yangzhou, China. Its market capitalization is roughly HKD 11 billion. In the fiscal year ended 2025-12-31, 9637 reported HKD 31M in revenue and (HKD 750M) in net income.
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | HKD 31M | HKD 6M |
| Gross Profit | HKD 13M | HKD 2M |
| Operating Income (EBIT) | (HKD 641M) | (HKD 307M) |
| Net Income | (HKD 750M) | (HKD 326M) |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | HKD 1.3B | HKD 1.1B |
| Total Liabilities | HKD 837M | HKD 2.5B |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9637 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms